drugset / Trial / NCT05269355
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
RandomizedParallel-groupTriple-blindTreatment
Summary
This study will compare the efficacy and safety of unesbulin plus dacarbazine versus placebo plus dacarbazine in participants with unresectable or metastatic, relapsed or refractory LMS who have received at least 1 prior line of systemic therapy.
Timeline
- Start
- 2022-05-23
- Primary completion
- 2024-06-17
- Completion
- 2024-07-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Unesbulin | Small molecule | 300 mg | Oral |
| Background | Dacarbazine | Small molecule | 1000 mg/m2 | Intravenous |